Navigation Links
InfraReDx's LipiScan(TM) Coronary Imaging System for Identification of Lipid Core Plaque to be Highlighted at 59th Annual Scientific Session of the American College of Cardiology
Date:3/10/2010

InfraReDx's LipiScan near-infrared (NIR) spectroscopy catheter is the only FDA-cleared product to detect and assess the intracoronary composition of lipid core plaque, which cannot be detected by commonly used diagnostic tests such as treadmill exams and coronary angiograms. Lipid core-containing plaque (LCP) is believed to be "vulnerable plaque" that can rupture and form dangerous blood clots leading to coronary thrombosis. LCP is widely considered to be responsible for a significant number of stenting procedure complications and is believed to be the primary cause of acute coronary events, the leading cause of death in the developed world.

"One of the biggest challenges facing interventional cardiologists today is the ability to detect vulnerable coronary and fatty plaques," said Brijeshwar S. Maini, M.D., F.A.C.C, co-chair cardiovascular research, Pinnacle Health at Harrisburg Hospital. "As a result of improved imaging and diagnostic capabilities, however, physicians can now be armed with that information and are able to make important advances and improvements in patient care. This year's ACC meeting provides us with a great opportunity to interact with our colleagues, share key learnings and discuss important steps forward."

"We are pleased to be working so closely with these world renowned cardiology experts and leaders as they strive to improve patient care and we advance our LipiScan coronary imaging system," said James E. Muller, M.D., founder and chief executive officer of
'/>"/>

SOURCE InfraReDx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. FDA Grants Market Clearance for the LipiScan(TM) Coronary Imaging System Developed by InfraReDx, Inc. - A Novel Spectroscopy System for the Identification of Lipid Core Containing Plaques of Interest in the Coronary Arteries
2. First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System
3. InfraReDx to Showcase the LipiScan(TM) Coronary Imaging System at the Cardiovascular Research Foundations (CRF) Annual Transcatheter Cardiovascular Therapeutics (TCT) Scientific Meeting
4. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
5. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
6. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
7. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
8. Surgery More Likely Than Angioplasty to Relieve Pain for Patients With Coronary Artery Disease
9. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
10. Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned
11. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... EDISON, N.J. , Aug. 4, 2015 /PRNewswire/ ... biopharmaceutical company focused on the development and commercialization ... Sapirstein , Chief Executive Officer, will present live ... DATE: Thursday, August 6, 2015 TIME: 12:15PM EDT ... will be a live, interactive online event where ...
(Date:8/4/2015)... Aug. 4, 2015 Among 1,000 U.S. consumers, ... only half of consumers surveyed are aware of prescription ... used use them, according to findings from a new ... service partnership focused on improving the health and well-being ... survey polled 1,000 men and women, ages 21 and ...
(Date:8/4/2015)... Calif., Aug. 4, 2015  Syneron Medical Ltd. (NASDAQ: ... financial results for the three month period ended June 30, ... Non-GAAP 1 Highlights: , Revenue ... currency. , North American product sales grew 45% year-over-year. ... constant currency, including 14% product growth in the EMEA region ...
Breaking Medicine Technology:ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com 2ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com 3New Study Finds Consumers are Leaving Money at the Pharmacy 2New Study Finds Consumers are Leaving Money at the Pharmacy 3Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 2Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 3Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 4Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 5Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 6Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 7Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 8Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 9Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 10Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 11Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 12Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 13Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 14Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 15Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 16Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 17
... ... ... ... ...
... ... ... ... ...
Cached Medicine Technology:PARI Pharma's Altera Delivers Gilead's Cayston, Approved by the U.S. FDA for the Improvement of Respiratory Symptoms in Cystic Fibrosis Patients With Pseudomonas aeruginosa 2PARI Pharma's Altera Delivers Gilead's Cayston, Approved by the U.S. FDA for the Improvement of Respiratory Symptoms in Cystic Fibrosis Patients With Pseudomonas aeruginosa 3PARI Pharma's Altera Delivers Gilead's Cayston, Approved by the U.S. FDA for the Improvement of Respiratory Symptoms in Cystic Fibrosis Patients With Pseudomonas aeruginosa 4PARI Pharma's Altera Delivers Gilead's Cayston, Approved by the U.S. FDA for the Improvement of Respiratory Symptoms in Cystic Fibrosis Patients With Pseudomonas aeruginosa 5PARI Pharma's Altera Delivers Gilead's Cayston, Approved by the U.S. FDA for the Improvement of Respiratory Symptoms in Cystic Fibrosis Patients With Pseudomonas aeruginosa 6Diabetics Twice as Likely to Have Hearing Loss; North Carolina HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 2Diabetics Twice as Likely to Have Hearing Loss; North Carolina HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 3Diabetics Twice as Likely to Have Hearing Loss; North Carolina HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 4Diabetics Twice as Likely to Have Hearing Loss; North Carolina HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 5Diabetics Twice as Likely to Have Hearing Loss; North Carolina HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 6Diabetics Twice as Likely to Have Hearing Loss; North Carolina HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 7
(Date:8/4/2015)... ... 04, 2015 , ... Sin City Gallery is delighted to ... diverse group of exceptionally talented female artists. The exhibition premieres at the ... 25-27, 2015 in Downtown Las Vegas. Curated by gallery director Dr. Laura Henkel, ...
(Date:8/4/2015)... ... August 04, 2015 , ... MedicaSoft ... Office of the National Coordinator for Health Information Technology (ONC-HIT) 2014 Edition ... highest quality personal health record and patient portal solution to healthcare providers ...
(Date:8/4/2015)... ... August 04, 2015 , ... Driving skills may decline ... driving, says the August 2015 Harvard Health Letter. , "Age and health conditions ... an individual assessment of skills," says Lissa Kapust, a social worker at Harvard-affiliated ...
(Date:8/4/2015)... ... ... METTLER TOLEDO has announced an upcoming online symposium entitled ... and Merck. This free online seminar will be held on September 24, ... decisions with limited process understanding. Established methods have been developed to facilitate ...
(Date:8/4/2015)... ... August 04, 2015 , ... Half of consumers ... is board-certified is increasingly influential in their choice of practitioner, according to new ... Consumer Survey on Cosmetic Dermatologic Procedures reflects overall consumer views on cosmetic medical ...
Breaking Medicine News(10 mins):Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 2Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 3Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 4Health News:MedicaSoft's HealthCenter Earns ONC-HIT Certification from Drummond Group 2Health News:MedicaSoft's HealthCenter Earns ONC-HIT Certification from Drummond Group 3Health News:Assessment Can Help Older Drivers Keep Driving Safely, from the August 2015 Harvard Health Letter 2Health News:METTLER TOLEDO Announces New Process Chemistry and Scale-up Online Seminar 2Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 2Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 3Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 4
... without gestational diabetes signals future heart risk, researcher says. , ... given to pregnant women may also show if they have ... new study has found. , This finding is important because ... for gestational diabetes to identify women who are at risk ...
... Aug. 24 /PRNewswire-Asia-FirstCall/ -- China Kangtai Cactus,Biotech, Inc. (OTC ... marketer of a variety of cactus-based products in,China, announced ... attend investor conference and meet with U.S. investors in ... roadshow details: , The company ...
... , WASHINGTON, Aug. 24 Secretary of ... (VA) is taking steps to assist Veterans seeking compensation for Post-Traumatic ... of war are being addressed vigorously and comprehensively by this administration ... century," said Secretary Shinseki. , , The VA ...
... , , AUBURN HILLS, ... (OTC Bulletin Board: ECOC), a leader in the discovery ... that it has signed a collaboration agreement with a ... for producing "fire standard compliant" (FSC) cigarettes. FSC cigarettes ...
... , ABBOTT PARK, Ill., Aug. 24 ... has received approval from Health Canada for the XIENCE V(R) Everolimus ... (CAD). XIENCE V is the only drug eluting stent to have ... the primary endpoints of two randomized, pivotal (phase III) clinical trials. ...
... , , CINCINNATI and ARDEE, Ireland, Aug. 24, ... Warner Chilcott plc (Nasdaq: WCRX ) today announced an agreement for ... cash payment of $3.1 billion. , , To view ... m nr/pg/39814/ , , (Logo: ...
Cached Medicine News:Health News:Glucose Challenge in Pregnancy Could Predict Heart Disease 2Health News:China Kangtai Cactus Biotech to Attend Rodman & Renshaw Conference and Meet with Investors in September 2Health News:China Kangtai Cactus Biotech to Attend Rodman & Renshaw Conference and Meet with Investors in September 3Health News:Secretary Shinseki Moves to Simplify PTSD Compensation Rules 2Health News:Ecology Coatings Signs Development Agreement with Major U.S. Tobacco Company 2Health News:Ecology Coatings Signs Development Agreement with Major U.S. Tobacco Company 3Health News:Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent 2Health News:Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent 3Health News:Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent 4Health News:Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent 5Health News:Warner Chilcott Acquires P&G's Global Pharmaceuticals Business 2Health News:Warner Chilcott Acquires P&G's Global Pharmaceuticals Business 3Health News:Warner Chilcott Acquires P&G's Global Pharmaceuticals Business 4Health News:Warner Chilcott Acquires P&G's Global Pharmaceuticals Business 5Health News:Warner Chilcott Acquires P&G's Global Pharmaceuticals Business 6Health News:Warner Chilcott Acquires P&G's Global Pharmaceuticals Business 7Health News:Warner Chilcott Acquires P&G's Global Pharmaceuticals Business 8
...
... Tupos LV/A+, the single-lead principle has been applied ... The complete system, which consists of the Tupos ... the scope of surgery and the risk of ... and the ventricle via a single lead. The ...
... ICD cardiac resynchronization and ICD device offers ... The unit's RV only sensing provides no ... LV depolarizations, eliminating this cause of inappropriate ... LV separation for optimized hemodynamics. Proven PR ...
... The Medtronic InSync II Marquis incorporates ... ICD therapy. Cardiac resynchronization benefits include ... pacing outputs to unique patient needs. ... functions that help physicians manage heart ...
Medicine Products: